Position in ERAS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$2,640,446
New position
Shares Held
163,192
first reported quarter
Ownership
0.052%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026NATIXIS holds $79,787,364 across 30 Biotechnology names. ERAS ranks #4 (3.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
55,307 | $42,732,400 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
48,192 | $21,519,655 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
17,076 | $5,649,936 | |
| 4 | ERAS |
Erasca, Inc.
This page
|
163,192 | $2,640,446 | |
| 5 | RARE |
Ultragenyx Pharmaceutical Inc.
|
81,754 | $1,712,746 | |
| 6 | COGT |
Cogent Biosciences, Inc.
|
41,536 | $1,598,720 | |
| 7 | CAI |
Caris Life Sciences, Inc.
|
52,778 | $943,670 | |
| 8 | TECH |
BIO-TECHNE Corp
|
11,286 | $589,806 |
All Filings in ERAS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,640,446 | 163,192 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||